NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

China SXT Pharmaceuticals, Inc. (SXTC) Stock Analysis

China SXT Pharmaceuticals, Inc. (SXTC) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SXTC

$0.073

+$0.0077 (+11.79%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SXTC with… →

SXTC Key Statistics

As of Oct 21, 2026
Trading
Open
$0.0732
Previous Close
$0.0653
Day's Range
0.066–0.0922
52-Week Range
0.061–83,760.00
Volume
226.60M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.86
Valuation
Market Cap
$756.10K
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.66
EPS (ttm)Profit attributable to each share over the last twelve months.
−730.40
Financials (FY)
Revenue (FY)
$1.14M−34.63%
Net Income (FY)
−$6.21M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
10.36M
1-Year Return
−100.00%
Dividend and dates
Avg Volume
16.51M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SXTC closed at $0.073, −100.00% over 1 year.

China SXT Pharmaceuticals, Inc. (SXTC) has a market capitalization of $756.10K.

In fiscal 2025, SXTC reported revenue of $1.14M.

SXTC Stock Return by Calendar Year

China SXT Pharmaceuticals, Inc. (SXTC) return since Jan 2019: what $10,000 became

1 year
$10,000 $0.04
−99.9996%
5 years
$10,000 $0.002
−99.99998%
Since Jan 2019
$10,000 $0.0001
−99.999999%

If you had invested $10,000 in China SXT Pharmaceuticals, Inc. (SXTC) at the close on January 4, 2019, the earliest close on record here, it would have been worth $0.0001 at the close on October 21, 2026: −99.999999% in total, −90.52% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−100.00%
2025+214.96%
2024−87.20%
2023−70.70%
2022−16.62%
2021−50.61%
2020−59.88%
2019−85.71%

As of October 21, 2026.

SXTC Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025$1.14M−$6.21M−545.2%
2024$1.74M−$3.30M−189.8%
2023$1.93M−$3.10M−160.7%
2022$1.97M−$5.93M−301.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$1.14M$248.70K−$7.12M−$6.21M−545.2%
2024$1.74M$367.43K−$2.68M−$3.30M−189.8%
2023$1.93M$553.97K−$2.52M−$3.10M−160.7%
2022$1.97M$426.27K−$5.61M−$5.93M−301.0%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

SXTC Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricSXTCDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.662.100.3x the median

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values China SXT Pharmaceuticals, Inc. (SXTC) at $756.10K. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 56 employees.

The most recent close on file for SXTC is $0.073, dated October 21, 2026. That is +$0.0077 (+11.79%) against the previous close. The 52-week range on file runs from $0.061 to $83,760.00. The latest close sits 19.67% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $1.14M. That is −34.63% against the prior fiscal year, when revenue was $1.74M. The same year closed with a net loss of $6.21M. Trailing earnings per share are −730.4.

Across the 4 fiscal years on file, revenue moves from $1.97M in 2022 to $1.14M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 0.66. On price-to-sales that is 0.3 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year total return is −100.00%. Across 5 years the annualized return works out at −95.28%. The reported beta is 1.86. Annualized volatility over the trailing 7 years is 655.86%.

Growth & Income

The record shows no dividend for SXTC.

The strongest complete calendar year on file is 2025 at +214.96%; the weakest is 2024 at −87.20%. Of the 7 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −100.00% year to date.

Peer Comparison

China SXT Pharmaceuticals, Inc. (SXTC) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
China SXT Pharmaceuticals, Inc. SXTC $756.10K —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. China SXT Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About China SXT Pharmaceuticals, Inc.

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.

Visit website →